Brief: Bioarctic Leqembi® Approved For Iv Maintenance Treatment In China
29/09/2025 07:25
Sept 29 (Reuters) - BioArctic AB BIOAb.ST: LEQEMBI® APPROVED FOR IV MAINTENANCE TREATMENT IN CHINA Source text: ID:nWkr5LHr9V Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln